Latest Ibutilide Stories

CAMBRIDGE, England, March 20, 2012 /PRNewswire/ -- XEN-D0103, a potent and selective Kv1.5 antagonist, is safe and well tolerated in healthy volunteers XENTION LTD, the Cambridge-based biopharmaceutical company specialising in the discovery and development of ion channel-modulating drugs, reported positive data today from a phase 1 trial of XEN-D0103 administered orally. The drug, a selective inhibitor of the cardiac potassium channel Kv1.5, was well tolerated and...

LAKE FOREST, Ill., Jan. 12 /PRNewswire/ -- Bioniche Pharma, a leading developer and manufacturer of injectable pharmaceuticals announced today the launch of Ibutilide Fumarate Injection, the generic equivalent of Corvert® from Pfizer Inc. (Logo: http://www.newscom.com/cgi-bin/prnh/20080702/AQW070LOGO) "The addition of Ibutilide Fumarate Injection further demonstrates Bioniche Pharma's continued growth and dedication to a consistently expanding portfolio of injectables," said George...

Atrial fibrillation is an irregular heartbeat (arrhythmia) in which the atria, or upper chambers of the heart, beat quickly and inconsistently. Expression of potassium channel KCNA5 is confined to cells in the atria and not the ventricle, making it a target for the development of drugs to treat atrial fibrillation. Polymorphisms in KCNA5 have been identified, which make the potassium channel less sensitive to blockade by antiarrhythmic drugs, but appear otherwise indistinguishable from normal...